Search research articles
Contact Us
Filters
Showing results (71-80 of 99) with videos related to
Page
of 10
Sort By:
American Heart Journal
|
March 3, 2015
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators
Javed Butler, Gregg C Fonarow, Christopher O'Connor, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy
Ahmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
JACC. Heart Failure
|
March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF
David E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.
Circulation
|
September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial
Joseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
European Heart Journal
|
March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Albree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Circulation. Heart Failure
|
November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
Xiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Journal of the American College of Cardiology
|
October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
JACC. Heart Failure
|
February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
JAMA Cardiology
|
September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial
Matthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 99) with videos related to
Sort By:
Page
of 10
American Heart Journal
|
March 3, 2015
Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators
Javed Butler, Gregg C Fonarow, Christopher O'Connor, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy
Ahmad Masri, Rhanderson N Cardoso, Theodore P Abraham, et al.
JACC. Heart Failure
|
March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF
David E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.
Circulation
|
September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial
Joseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
European Heart Journal
|
March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Albree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Circulation. Heart Failure
|
November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
Xiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Journal of the American College of Cardiology
|
October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Ahmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology
|
September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
JACC. Heart Failure
|
February 5, 2025
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, et al.
JAMA Cardiology
|
September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial
Matthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
Page
of 10